4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-024901
PRESIDENT AND CEO sold 14,936 shares at an average $27.51 ($410,867)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kintz Samuel PRESIDENT AND CEO | 2024-10-04 | Sale 10b5-1 | −12,206 | $27.51 | $335,792 | 1,036,523 | I: show line 1 in the form |
| Kintz Samuel PRESIDENT AND CEO | 2024-10-07 | Sale 10b5-1 | −2,730 | $27.50 | $75,075 | 1,033,793 | I: show line 2 in the form |
| Open-market sales · 14,936 sh · avg $27.51 · $410,867 | |||||||
Loading xslF345X05/form4-10082024_101015.xml…